Thursday, September 8, 2011, 7:12 AM
PerkinElmer (PKI) agrees to buy Caliper Life Sciences (CALP) for $10.50 a share, a 42% premium over yesterday's closing price. The $600M deal adds "innovative molecular imaging and detection technologies" to PerkinElmer's portfolio, according to its CEO. Shares of CALP +40% premarket.
Comment![M&A]
Tuesday, February 1, 2011, 11:39 AM
With the 2011 Advances in Genome Biology and Technology conference getting underway tomorrow, life sciences companies may get a little extra attention. Major presenters/participants include Illumina (ILMN), Life Technologies (LIFE), Caliper Life Sciences (CALP), Agilent (A), Pacific Biosciences (PACB), and Complete Genomics (GNOM).
Comment!
Jim Van Meerten CALP - Caliper Life Sciences-96% Barchart buy signal-16new highs and up 14.26% in the last month - Relative Strength Index 79.47% and rising
12/27/10
Reply
•!Report Abuse
View all 0 replies
Jim Van Meerten CALP- Caliper Life Sciences- 96% Barchart buy signal-15 new highs and up 47.15% last month-Relative strength Index 85.94 and rising
11/21/10
Reply
•!Report Abuse
View all 0 replies
LATEST REPLIES
24 people get CALP articles and Market Currents by email alert.